Patents by Inventor Maria Carmen Valcarce-Lopez

Maria Carmen Valcarce-Lopez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
    Patent number: 10064846
    Abstract: The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: September 4, 2018
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Maria Carmen Valcarce Lopez
  • Glucokinase activator compositions for the treatment of diabetes
    Patent number: 10004782
    Abstract: The present invention relates to pharmaceutical compositions comprising {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid (FRI-1) in combination with an anti-diabetic drug selected from the group consisting of metformin, sitagliptin or exenatide. The present invention also relates to the use of the pharmaceutical compositions in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: June 26, 2018
    Assignee: vTv Therapeutics LLC
    Inventors: Maria Carmen Valcarce Lopez, Tung Fong
  • Use of a ppar-delta agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb
    Patent number: 9968613
    Abstract: The present invention provides methods for reducing loss of muscle strength, muscle mass, or Type I muscle fibers in an immobilized limb by administering (E)-[4-[3-(4-Fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: May 15, 2018
    Assignee: VTV THERAPEUTICS LLC
    Inventors: Maria Carmen Valcarce Lopez, Eliot Ohlstein
  • Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
    Patent number: 9855251
    Abstract: The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: January 2, 2018
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Maria Carmen Valcarce Lopez
  • Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase Activator
    Publication number: 20170354647
    Abstract: The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.
    Type: Application
    Filed: August 28, 2017
    Publication date: December 14, 2017
    Inventors: Adnan M.M. Mjalli, Maria Carmen Valcarce Lopez
  • Treatment of Mild and Moderate Alzheimer's Disease
    Publication number: 20170326113
    Abstract: The present invention relates to methods of treatment using [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine (“COMPOUND I”) or a pharmaceutically acceptable salt thereof. In various embodiments, the methods of treatment include treatment of mild-to-moderate dementia of Alzheimer's type, diabetes, insomnia, and other indications. The present invention also relates to pharmaceutical compositions comprising COMPOUND I or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 23, 2017
    Publication date: November 16, 2017
    Inventors: Cesare Orlandi, David J. Clark, Imogene M. Dunn, Maria Carmen Valcarce Lopez, Matthew J. Kostura
  • Treatment of mild and moderate Alzheimer's disease
    Patent number: 9717710
    Abstract: The present invention relates to methods of treatment using [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine (“COMPOUND I”) or a pharmaceutically acceptable salt thereof. In various embodiments, the methods of treatment include treatment of mild-to-moderate dementia of Alzheimer's type, diabetes, insomnia, and other indications. The present invention also relates to pharmaceutical compositions comprising COMPOUND I or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: August 1, 2017
    Assignee: vTv THERAPEUTICS LLC
    Inventors: Cesare Orlandi, David J. Clark, Imogene M. Dunn, Maria Carmen Valcarce Lopez, Matthew J. Kostura
  • USE OF A PPAR-DELTA AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB
    Publication number: 20170027950
    Abstract: The present invention provides methods for reducing loss of muscle strength, muscle mass, or Type I muscle fibers in an immobilized limb by administering (E)-[4-[3-(4-Fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 6, 2016
    Publication date: February 2, 2017
    Inventors: Maria Carmen Valcarce Lopez, Eliot Ohlstein
  • Use of a PPAR-delta agonist for treating muscle atrophy
    Patent number: 9487493
    Abstract: The present invention provides methods for treating muscle atrophy by administering a PPAR? agonist.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: November 8, 2016
    Assignee: vTv Therapeutics LLC
    Inventors: Maria Carmen Valcarce Lopez, Eliot Ohlstein
  • Use of Metformin in Combination with a Glucokinase Activator and Compositions Comprising Metformin and a Glucokinase Activator
    Publication number: 20160184277
    Abstract: The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.
    Type: Application
    Filed: February 11, 2016
    Publication date: June 30, 2016
    Inventors: Adnan M.M. Mjalli, Maria Carmen Valcarce Lopez
  • Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
    Patent number: 9359313
    Abstract: The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: June 7, 2016
    Assignee: vTv Therapeutics LLC
    Inventors: Adnan M. M. Mjalli, Maria Carmen Valcarce Lopez
  • Combinations of a GLP1R Agonist and Metformin and Use Thereof for the Treatment of Type 2 Diabetes and Other Disorders
    Publication number: 20150313908
    Abstract: The present invention provides uses of a glucagon-like peptide 1 receptor agonist in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GLP1R agonist and metformin.
    Type: Application
    Filed: July 14, 2015
    Publication date: November 5, 2015
    Inventors: Adnan M.M. Mjalli, Bradley Alan Clark, Dharma Rao Polisetti, James C. Quada, JR., Maria Carmen Valcarce Lopez, Robert Carl Andrews, Stephen Thomas Davis, Thomas Scott Yokum
  • USE OF A PPAR-DELTA AGONIST FOR TREATING MUSCLE ATROPHY
    Publication number: 20150072985
    Abstract: The present invention provides methods for treating muscle atrophy by administering a PPAR? agonist.
    Type: Application
    Filed: September 5, 2014
    Publication date: March 12, 2015
    Inventors: Maria Carmen Valcarce Lopez, Eliot Ohlstein
  • Treatment of Mild and Moderate Alzheimer's Disease
    Publication number: 20140100218
    Abstract: The present invention relates to methods of treatment using [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine (“COMPOUND I”) or a pharmaceutically acceptable salt thereof. In various embodiments, the methods of treatment include treatment of mild-to-moderate dementia of Alzheimer's type, diabetes, insomnia, and other indications. The present invention also relates to pharmaceutical compositions comprising COMPOUND I or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 22, 2013
    Publication date: April 10, 2014
    Applicant: TransTech Pharma, LLC
    Inventors: Cesare Orlandi, David J. Clark, Imogene M. Grimes, Maria Carmen Valcarce Lopez, Matthew J. Kostura
  • Glucokinase Activator Compositions for the Treatment of Diabetes
    Publication number: 20140066372
    Abstract: The present invention relates to pharmaceutical compositions comprising {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid (FRI-1) in combination with an anti-diabetic drug selected from the group consisting of metformin, sitagliptin or exenatide. The present invention also relates to the use of the pharmaceutical compositions in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.
    Type: Application
    Filed: November 5, 2013
    Publication date: March 6, 2014
    Applicant: TransTech Pharma, LLC
    Inventors: Maria Carmen Valcarce Lopez, Tung Fong
  • Heteroaryl-ureas and their use as glucokinase activators
    Patent number: 8263634
    Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: September 11, 2012
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsø, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswarak Santhosh
  • USE OF METFORMIN IN COMBINATION WITH A GLUCOKINASE ACTIVATOR AND COMPOSITIONS COMPRISING METFORMIN AND A GLUCOKINASE ACTIVATOR
    Publication number: 20110313007
    Abstract: The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The invention also provides a salt formed between metformin and a GK activator.
    Type: Application
    Filed: May 24, 2011
    Publication date: December 22, 2011
    Applicant: TransTech Pharma, Inc.
    Inventors: Adnan M.M. Mjalli, Maria Carmen Valcarce Lopez
  • ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS
    Publication number: 20110301158
    Abstract: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Application
    Filed: August 15, 2011
    Publication date: December 8, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Dharma Rao Polisetti, Janos Tibor Kodra, Jesper Lau, Paw Bloch, Maria Carmen Valcarce-Lopez, Niels Blume, Mustafa Guzel, Kalpathy Chidambareswaran Santhosh, Adnan M.M. Mjalli, Robert Carl Andrews, Govindan Subramanian, Michael Ankersen, Per Vedso, Anthony Murray, Lone Jeppesen
  • Aryl carbonyl derivatives as therapeutic agents
    Patent number: 8063081
    Abstract: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: November 22, 2011
    Assignee: Novo Nordisk A/S
    Inventors: Dharma Rao Polisetti, Janos Tibor Kodra, Jesper Lau, Paw Bloch, Maria Carmen Valcarce Lopez, Niels Blume, Mustafa Guzel, Kalpathy Chidambareswaran Santhosh, Adnan M. M. Mjalli, Robert Carl Andrews, Govindan Subramanian, Michael Ankersen, Per Vedso, Anthony Murray, Lone Jeppesen
  • Heteroaryl-ureas and their use as glucokinase activators
    Patent number: RE45183
    Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: October 7, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsoe, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswaran Santhosh